The recent research on the regulation of glucose metabolism and breast cancer treatment suggested that alterations in bioenergetics play a role in resistance to trastuzumab and glycolysis inhibition in combination with trastuzumab induced more efficient inhibition of glycolysis in ErbB2-positive breast cancer cells [38]. The gene discussed is ERBB2; the disease is breast cancer.